Methotrexate and lung disease in rheumatoid arthritis: A meta-analysis of randomized controlled trials

Arthritis and Rheumatology

Volumn 66, Issue 4, 2014, Pages 803-812

  Conway, Richard ^a   Low, Candice ^b   Coughlan, Robert J ^a   O'Donnell, Martin J ^c   Carey, John J ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADVERSE OUTCOME; ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION RISK; INTERSTITIAL LUNG DISEASE; META ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; LUNG DISEASES; METHOTREXATE; RISK;

EID: 84898613366     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38322     Document Type: Article

References (64)

1. Brooks PM,. The burden of musculoskeletal disease: global perspective. Clin Rheumatol 2006; 25: 778-81.
2. Meune C, Touze E, Trinquart L, Allanore Y,. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009; 48: 1309-13.
3. Watson DJ, Rhodes T, Guess HA,. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196-202.
4. Sokka T, Abelson B, Pincus T,. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26: S35-61.
5. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
6. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
7. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62: 1583-91.
8. Khan ZA, Tripathi R, Mishra B,. Methotrexate: a detailed review on drug delivery and clinical aspects. Expert Opin Drug Deliv 2012; 9: 151-69.
9. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO,. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987; 16: 186-95.
10. McKendry RJ, Dale P,. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20: 1850-6.
11. Sostman HD, Matthay RA, Putman CE, Smith GJ,. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976; 55: 371-88.
12. Salliot C, van der Heijde D,. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68: 1100-4.
13. Sathi N, Chikura B, Kaushik VV, Wiswell R, Dawson JK,. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol 2012; 31: 79-83.
14. Chikura B, Sathi N, Lane S, Dawson JK,. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford) 2008; 47: 1647-50.
15. Schnabel A, Richter C, Bauerfeind S, Gross WL,. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997; 52: 377.
16. Mornex JF, Cordier G, Pages J, Vergnon JM, Lefebvre R, Brune J, et al. Activated lung lymphocytes in hypersensitivity pneumonitis. J Allergy Clin Immunol 1984; 74: 719-27.
17. Phillips TJ, Jones DH, Baker H,. Pulmonary complications following methotrexate therapy. J Am Acad Dermatol 1987; 16: 373-5.
18. Kaplan RL, Waite DH,. Progressive interstitial lung disease from prolonged methotrexate therapy. Arch Dermatol 1978; 114: 1800-2.
19. Dawson JK, Desmond J, Graham DR,. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology(Oxford) 2002; 41: 262-7.
20. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP,. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109: 933-8.
21. Saravanan V, Kelly CA,. Pulmonary function after methotrexate in rheumatoid arthritis: a one-year follow up study. Rheumatology (Oxford) 2002; 41 (Suppl 2): S145.
22. Antin-Ozerkis D, Evans J, Rubinowitz A, Homer RJ, Matthay RA,. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 2010; 31: 451-78.
23. Cortet B, Perez T, Roux N, Flipo RM, Duquesnoy B, Delcambre B, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 596-600.
24. Garcia JG, James HL, Zinkgraf S, Perlman MB, Keogh BA,. Lower respiratory tract abnormalities in rheumatoid interstitial lung disease: potential role of neutrophils in lung injury. Am Rev Respir Dis 1987; 136: 811-7.
25. Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156: 528-35.
26. Turesson C, Matteson EL, Colby TV, Vuk-Pavlovic Z, Vassallo R, Weyand CM, et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 2005; 52: 73-9.
27. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-37.
28. Grove ML, Hassell AB, Hay EM, Shadforth MF,. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 2001; 94: 309-19.
29. Searles G, McKendry RJ,. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors: four case reports and a review of the literature. J Rheumatol 1987; 14: 1164-71.
30. Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
31. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
32. Ishaq M, Muhammad JS, Hameed K, Mirza AI,. Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 375-80.
33. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD Study. Ann Rheum Dis 2010; 69: 1129-35.
34. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
35. Wei W, Zhang LL, Xu JH, Xiao F, Bao CD, Ni LQ, et al. A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Res Ther 2009; 11: R180.
36. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
37. Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 2009; 61: 979-87.
38. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-9.
39. Hu D, Bao C, Chen S, Gu J, Li Z, Sun L, et al. A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. Rheumatol Int 2009; 29: 297-303.
40. Zhang LL, Wei W, Xiao F, Xu JH, Bao CD, Ni LQ, et al. A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 905-10.
41. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-7.
42. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063-74.
43. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
44. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
45. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al, for the Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984-92.
46. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
47. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-65.
48. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB,. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082-8.
49. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
50. Rau R, Herborn G, Menninger H, Blechschmidt J,. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997; 36: 345-52.
51. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
52. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992; 35: 259-69.
53. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: a thirty-six-week, double-blind trial. Arthritis Rheum 1990; 33: 330-8.
54. Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM,. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013; 65: 334-42.
55. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
56. Sinha A, Silverstone EJ, O'Sullivan MM,. Gold-induced pneumonitis: computed tomography findings in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 712-4.
57. Chikura B, Lane S, Dawson JK,. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009; 48: 1065-8.
58. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007; 66: 235-41.
59. Boyd O, Gibbs AR, Smith AP,. Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis. Br J Rheumatol 1990; 29: 222-4.
60. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X,; BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011; 124: 386-94.
61. Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostor AJ,. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases: a systematic literature review. Rheumatology (Oxford) 2011; 50: 2297-305.
62. Pearce F, Johnson SR, Courtney P,. Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford) 2012; 51: 578-80.
63. Ameen M, Taylor DA, Williams IP, Wells AU, Barkert JN,. Pneumonitis complicating methotrexate therapy for pustular psoriasis. J Eur Acad Dermatol Venereol 2001; 15: 247-9.
64. Cook NJ, Carroll GJ,. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis 1992; 51: 272-4.